News & Updates
Filter by Specialty:

3-year RUBY data support add-on dostarlimab as frontline Tx for endometrial cancer
17 Apr 2025
byAudrey Abella
At the second interim analysis of part 1 of the phase III RUBY study, updated duration of response (DoR) findings suggest that women with primary advanced or recurrent endometrial cancer who have achieved a response with the combination regimen comprising dostarlimab and carboplatin-paclitaxel (CP) have substantially improved DoR.
3-year RUBY data support add-on dostarlimab as frontline Tx for endometrial cancer
17 Apr 2025
Testosterone recovery after ADT tied to improved OS in prostate cancer
16 Apr 2025
byStephen Padilla
Testosterone recovery to a normal level appears predictive of improved overall survival (OS) among men with intermediate-risk prostate cancer who underwent androgen-deprivation therapy (ADT) and radiation therapy (RT), suggests a study.